Form 4: Twist Bioscience Exec Sells Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp, reported transactions involving the sale of common stock and the acquisition of shares under a Rule 10b5-1 trading plan.

Summary

• Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation, executed a series of stock transactions on April 21st and 22nd, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan, adopted on May 27, 2025, which provides an affirmative defense against insider trading allegations.
• Leproust acquired 1,610 shares on April 21, 2026, at a price of $8.82 per share, and an additional 8,061 shares on April 22, 2026, also at $8.82 per share.
• Concurrently, she disposed of shares, with 1,610 shares sold on April 21, 2026, at a weighted average price of $65.01, and 7,910 shares sold on April 22, 2026, at a weighted average price of $65.275.
• Further sales on April 22, 2026, included 151 shares at $66.00.
• Following these transactions, Leproust's beneficial ownership of common stock stands at 858,887 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by a CEO can sometimes be perceived negatively, the explicit mention of a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a planned, strategic divestment.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially diversified selling strategies, which can be viewed positively for corporate governance.
• The acquisition of shares at a lower price ($8.82) alongside sales at significantly higher prices ($65.01 - $66.00) suggests a strategic execution of the trading plan.

Negatives

• The disposal of a significant number of shares by a key executive, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The weighted average sale prices indicate a substantial difference from the acquisition price, highlighting a significant gain realized by the reporting person.

Risks

• While the Rule 10b5-1 plan provides a defense, any perceived deviation or unusual activity within the plan could still attract regulatory scrutiny.
• The sale of shares by a CEO could be misinterpreted by the market as a negative signal about the company's future prospects, despite the plan's existence.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology sector. The use of Rule 10b5-1 plans by executives is a standard practice to manage personal stock portfolios while adhering to insider trading regulations, especially for companies with significant stock-based compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the CEO's stock sales as a neutral event due to the Rule 10b5-1 plan, but could also lead to minor short-term sentiment shifts.
• Employees: The stock sales by a senior executive might not have a direct impact, but could influence perceptions of executive confidence.
• Management: The use of the 10b5-1 plan reinforces established procedures for executive stock management.

Next Steps

• Continued monitoring of insider transactions for any further changes in beneficial ownership.
• Analysis of future filings to observe any new trading plans or modifications to existing ones.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Stock Acquisition, Beneficial Ownership, Twist Bioscience, Emily M. Leproust, SEC Filing, Executive Compensation